Table 3.
Results for all patients diagnosed with depression with/without anxiety [Hamilton Rating Scale for Depression (HAM-D) score ≥ 20] and for all patients diagnosed with anxiety only [Hamilton Rating Scale for Anxiety (HAM-A) score ≥ 18], assuming a 3-year time horizon
| IDgenetix®-guided treatment | TAU | |
|---|---|---|
| Patients with depression with/without anxiety (anxiety only excluded) and HAM-D score ≥ 20 | ||
| Patients achieved remission (%) | 79 (77–82) | 65 (62–68) |
| QALYs gained per patient | 2.10 (2.07–2.13) | 1.93 (1.90–1.96) |
| Total cost per patient ($US) | 14,005 (13,387–14,570) | 14,977 (14,347–15,636) |
| Incremental QALYs | 0.17 | Reference |
| Incremental total costs (US$) | − 972 | Reference |
| Incremental cost-effectiveness ratio (US$ per QALY) based on incremental total costs | Dominant (cost saving) | Reference |
| Patients with anxiety only and HAM-A score ≥ 18 | ||
| Patients achieved remission (%) | 77 (74–80) | 68 (65–71) |
| QALYs gained per patient | 2.08 (2.05–2.11) | 1.96 (1.93–1.99) |
| Total cost per patient (US$) | 14,602 (13,978–15,210) | 14,579 (13,976–15,237) |
| Incremental QALYs | 0.12 | Reference |
| Incremental total costs (US$) | 4 | Reference |
| Incremental cost-effectiveness ratio (US$ per QALY) based on incremental total costs | 35 | Reference |
QALYs quality-adjusted life-years, TAU treatment as usual